Science Corp just closed a massive $230 million funding round, vaulting the brain-computer interface startup to a $1.25 billion valuation as it races to bring its vision-restoring implant to patients. The round signals surging investor confidence in neurotech beyond the Neuralink hype, with Khosla Ventures and Lightspeed Venture Partners betting big on founder Max Hodak's vision. For an industry where regulatory pathways are notoriously slow, the capital infusion gives Science Corp serious runway to navigate FDA approvals while competing head-to-head with Elon Musk's better-known rival.
Science Corp is making a bold play in the brain implant race. The company founded by Max Hodak, who previously co-founded Neuralink before parting ways with Elon Musk, just locked down $230 million in fresh capital. Sources familiar with the financing tell TechCrunch the round values Science at $1.25 billion post-money, marking one of the largest neurotech funding events of the year.
The timing is strategic. While Neuralink dominates headlines with its motor-control focused implants and recent human trials, Science Corp has been quietly advancing its own approach: a retinal prosthetic called Prima designed to restore functional vision to people with age-related macular degeneration. The device works differently than Neuralink's brain chip, sitting on the surface of the retina rather than penetrating deep into brain tissue.
Khosla Ventures and Lightspeed Venture Partners led the round, with participation from Science's early backers including Y Combinator. The investor lineup reflects growing mainstream VC appetite for medical devices that once seemed like pure science fiction. Khosla in particular has doubled down on biotech infrastructure plays, betting that brain-computer interfaces will move from experimental to standard-of-care within the decade.
Hodak's departure from Neuralink in 2021 raised eyebrows, but Science Corp's progress suggests he's been executing on a deliberate roadmap. The company already completed early-stage human trials in Europe, where regulatory pathways for medical devices can move faster than in the U.S. According to data presented at ophthalmology conferences last year, some trial participants regained enough vision to read large print and recognize faces - outcomes that could qualify the device for FDA breakthrough designation.
The $230 million war chest addresses Science's most critical bottleneck: scaling manufacturing while navigating the FDA's rigorous approval process for Class III medical devices. Sources indicate a significant portion will fund U.S.-based clinical trials required for commercial launch, likely targeting a 2028 market entry. That timeline puts Science roughly parallel with Neuralink's own commercialization plans, setting up a direct race between Hodak and his former co-founder.
But the competition extends beyond just these two players. Synchron, another brain-computer interface startup, already has its device implanted in U.S. patients through FDA trials and doesn't require open brain surgery. Paradromics is advancing its own high-bandwidth brain implant. The sector is getting crowded fast, with each company targeting slightly different applications - motor control, vision restoration, communication for paralyzed patients.
What sets Science apart is the medical need it's addressing. Age-related macular degeneration affects more than 11 million Americans, a patient population orders of magnitude larger than candidates for motor-control implants. The market opportunity is massive if Science can prove its device works reliably and safely over years of use. Insurance reimbursement will be critical, and the company's clinical trial design appears focused on generating the outcomes data payers will demand.
The $1.25 billion valuation is notable but not outrageous given the sector dynamics. Neuralink reportedly raised at a $5 billion valuation last year, though that figure includes the Musk premium and broader brain-interface ambitions. Science's more focused approach on vision restoration gives it a clearer path to revenue, even if the total addressable market is narrower than Neuralink's everything-brain-related pitch.
Investors are also betting on Hodak's execution track record. Before Neuralink, he built Transcriptic, a cloud-based life sciences research platform that proved he could navigate complex regulated industries. His technical credibility in neuroscience is well-established, and he's assembled a team that includes veterans from medical device giants like Boston Scientific who know how to shepherd products through FDA approval.
The funding environment for deep-tech startups has been brutal over the past two years, making Science's ability to raise at this scale even more impressive. VCs have retreated from capital-intensive hardware plays with long development timelines, preferring software businesses with faster paths to revenue. That Science could pull together $230 million suggests investors see neurotech entering a new phase where the technology risk has diminished enough to justify the capital requirements.
What happens next will test whether the brain-computer interface hype can translate into actual medical products that help real patients. Science Corp now has the resources to find out, and the pressure is on to deliver results that justify the unicorn valuation.
Science Corp's $230 million raise is more than just another funding announcement - it's a signal that the brain-computer interface sector is maturing from moonshot research into a genuine medical device category. With Hodak's track record, a differentiated product targeting a massive patient population, and now serious capital to navigate FDA approval, Science has what it needs to prove neurotech can deliver on its promises. The real test starts now: turning that $1.25 billion valuation into a device that actually restores vision to millions of patients who need it. If they pull it off, this funding round will look like the moment when brain implants went from sci-fi to standard care.
